GLP-1 receptor agonists show promise for treating obesity-related headache conditions like migraine and idiopathic intracranial hypertension through weight loss, but headache is also a recognized side effect of these drugs.
Dual headache relationshipGLP-1 receptor agonists can both treat obesity-related headache conditions through weight loss and cause headache as a medication side effect
What the researchers found
The review identifies a dual relationship between GLP-1 receptor agonists and headache:
**Therapeutic potential:**
- Weight reduction from GLP-1 RAs can improve IIH-related headaches by decreasing cerebrospinal fluid pressure
- Obesity increases migraine risk and chronification; weight loss may reduce migraine burden
- The gut-brain axis connection suggests additional mechanisms through which GLP-1 RAs may influence headache pathways
**Adverse effects:**
- Headache is a recognized side effect of GLP-1 receptor agonist therapy
- The mechanism by which GLP-1 RAs cause headache is not fully understood
The review emphasizes that understanding this dual relationship is important for clinical decision-making in obese patients with headache disorders.
Why it matters
With millions of people now taking GLP-1 drugs for weight loss and diabetes, understanding their effects on headache is clinically important. For obese patients who also suffer from chronic migraines or IIH, GLP-1 drugs could address both weight and headache simultaneously. But for patients who develop headaches as a side effect, clinicians need guidance on management. This review helps navigate this nuanced clinical picture.
How the study worked
This is a narrative review examining published studies on the relationship between GLP-1 receptor agonists and headache conditions. The authors analyzed evidence for GLP-1 RAs' effects on IIH, migraine, and gut-brain axis-mediated headache mechanisms, as well as data on headache as an adverse effect of these medications.
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis, which may introduce selection bias in the studies discussed. The mechanisms by which GLP-1 RAs both relieve and cause headaches are not fully elucidated. Most evidence for headache improvement comes from weight-loss-mediated effects rather than direct GLP-1 receptor mechanisms in headache pathways. Large-scale clinical trials specifically designed to assess GLP-1 RAs' effects on headache outcomes are lacking.
How to read the evidence
This is a narrative review synthesizing available evidence. While it provides a useful clinical framework, the underlying evidence for GLP-1 RAs in headache management comes from observational data and indirect weight-loss effects rather than randomized controlled trials designed to assess headache outcomes specifically.
When this study was published
Published in 2025, this review addresses a timely clinical question as GLP-1 drug prescribing has surged globally. The dual relationship between these drugs and headache is actively being studied.
The bigger picture
This review highlights an increasingly important clinical question as GLP-1 drugs become widely prescribed: how do these peptide drugs interact with neurological conditions? The connection between GLP-1 signaling, the gut-brain axis, and headache pathophysiology adds to growing evidence that these drugs have effects far beyond metabolism. Understanding these neurological interactions will be essential as GLP-1 drugs are prescribed to an ever-larger patient population.
Questions still open
- Do GLP-1 receptor agonists have direct effects on headache pathways beyond those mediated by weight loss?
- Which GLP-1 drug has the best headache side-effect profile for patients with pre-existing migraine?
- Could GLP-1 receptor agonists eventually be approved as a treatment for idiopathic intracranial hypertension?
Common questions
Can GLP-1 drugs like semaglutide cause headaches?
Could a GLP-1 drug actually help my migraines?
Read the original research
Headache and GLP-1 receptor agonists: when medications are therapeutic and when they contribute to the symptom.
Arquivos de neuro-psiquiatria, 83(10), 1-7
Citation
Ferreira, Erika Tavares; Garcia, Leidys Marina Pedrozo; Londero, Renata Gomes. (2025). Headache and GLP-1 receptor agonists: when medications are therapeutic and when they contribute to the symptom.. Arquivos de neuro-psiquiatria, 83(10), 1-7. https://doi.org/10.1055/s-0045-1812303